---
title: "DMRA.US (DMRA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DMRA.US/news.md"
symbol: "DMRA.US"
name: "DMRA.US"
parent: "https://longbridge.com/en/quote/DMRA.US.md"
datetime: "2026-03-11T17:48:02.050Z"
locales:
  - [en](https://longbridge.com/en/quote/DMRA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DMRA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DMRA.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/DMRA.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/DMRA.US/news.md)


# DMRA.US (DMRA.US) — Related News

### [12 Health Care Stocks Moving In Thursday's Intraday Session](https://longbridge.com/en/news/275788821.md)
*2026-02-12T17:05:51.000Z*
> In Thursday's intraday session, SCWorx (WORX) saw a significant gain of 52.7%, reaching $0.28, while NovoCure (NVCR) ros

### [12 Health Care Stocks Moving In Wednesday's Pre-Market Session](https://longbridge.com/en/news/275601402.md)
*2026-02-11T12:05:49.000Z*
> In Wednesday's pre-market session, Quince Therapeutics (QNCX) saw a significant gain of 62.2%, reaching $0.86, while Neu

### [BUZZ-Biopharma co Galecto drops after $275 mln stock sale](https://longbridge.com/en/news/275606525.md)
*2026-02-11T12:41:26.000Z*
> Biopharmaceutical company Galectosaw its shares drop 6.8% to $20.05 in premarket trading following a $275 million equity

### [Galecto Announces Pricing of $275 Million Underwritten Public Offering | GLTO Stock News](https://longbridge.com/en/news/275547543.md)
*2026-02-10T19:42:00.000Z*
> Galecto, Inc. has priced its underwritten public offering of 14,473,685 shares of common stock at $19.00 per share, aimi

### [Galecto Inc. Held Special Shareholder Meeting](https://longbridge.com/en/news/275462958.md)
*2026-02-10T13:03:49.000Z*
> Galecto Inc. held a special shareholder meeting on February 9, 2026, where stockholders approved the company's redomesti

### [Galecto Inc. Files Initial Beneficial Ownership Statement for Chief Operating Officer Sherwin Sattarzadeh](https://longbridge.com/en/news/273772901.md)
*2026-01-27T02:04:01.000Z*
> Galecto Inc. has filed an initial beneficial ownership statement (Form 3) with the U.S. SEC, listing Sherwin Sattarzadeh

### [Galecto Inc. Unveils Mutant CALR Antibody Program Targeting Myeloproliferative Neoplasms](https://longbridge.com/en/news/272275690.md)
*2026-01-12T13:15:59.000Z*
> Galecto Inc. has acquired Damora Therapeutics to enhance its portfolio with therapies for mutant CALR-driven myeloprolif

### [Galecto Acquires Damora and Expands Leadership Team](https://longbridge.com/en/news/272274079.md)
*2026-01-12T13:03:47.000Z*
> Galecto, Inc. has successfully acquired Damora, marking a significant milestone in its strategic expansion. This acquisi

### [Galecto CFO Lori Firmani Reports Disposal of Common Shares](https://longbridge.com/en/news/271700461.md)
*2026-01-06T21:30:46.000Z*
> Lori Firmani, CFO of Galecto Inc., reported the disposal of common shares. The full filing is available through the prov